普通人群中非酒精性脂肪性肝病和晚期肝纤维化的患病率及危险因素：法国全国性NASH-CO研究 - Suppr

Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study.

作者信息

Nabi Oumarou, Lacombe Karine, Boursier Jérôme, Mathurin Philippe, Zins Marie, Serfaty Lawrence

机构信息

Inserm UMR-S1136, IPLESP, Sorbonne Université, Paris, France.

Inserm UMR-S1136, IPLESP, Sorbonne Université, Paris, France; Infectious Diseases Department, Hôpital Saint-Antoine, APHP, Paris, France.

出版信息

Gastroenterology. 2020 Aug;159(2):791-793.e2. doi: 10.1053/j.gastro.2020.04.048. Epub 2020 May 4.

DOI:10.1053/j.gastro.2020.04.048

PMID:32376412

Abstract

摘要

相似文献

Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study.普通人群中非酒精性脂肪性肝病和晚期肝纤维化的患病率及危险因素：法国全国性NASH-CO研究

Gastroenterology. 2020 Aug;159(2):791-793.e2. doi: 10.1053/j.gastro.2020.04.048. Epub 2020 May 4.

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.非酒精性脂肪性肝病无脂肪性肝炎患者中显著纤维化的患病率和危险因素。

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6. doi: 10.1016/j.cgh.2019.01.027. Epub 2019 Jan 29.

Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.美国非酒精性脂肪性肝炎相关肝硬化的患病率：基于国家健康与营养检查调查数据的分析

Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14.

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.成人糖尿病和非酒精性脂肪性肝病患者非酒精性脂肪性肝炎和晚期肝纤维化的临床模型：非酒精性脂肪性肝病转诊指南

Diabetes Care. 2015 Jul;38(7):1347-55. doi: 10.2337/dc14-1239. Epub 2015 Apr 17.

Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.肌肉减少症与非酒精性脂肪性肝病患者的严重肝纤维化有关。

Aliment Pharmacol Ther. 2017 Feb;45(4):510-518. doi: 10.1111/apt.13889. Epub 2016 Dec 27.

Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis.环氧合酶衍生的环氧二十碳三烯酸介质与非酒精性脂肪性肝病、非酒精性脂肪性肝炎及肝纤维化相关。

Gastroenterology. 2020 Dec;159(6):2232-2234.e4. doi: 10.1053/j.gastro.2020.08.001. Epub 2020 Aug 5.

Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection.人类免疫缺陷病毒单一感染中非酒精性脂肪性肝病的患病率及危险因素

AIDS. 2017 Jul 17;31(11):1621-1632. doi: 10.1097/QAD.0000000000001504.

Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016.2 型糖尿病中非酒精性脂肪肝疾病的筛查策略：来自 NHANES 2005-2016 的见解。

Diabetes Res Clin Pract. 2020 Sep;167:108358. doi: 10.1016/j.diabres.2020.108358. Epub 2020 Jul 31.

Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis.非酒精性脂肪性肝炎所致肝硬化患者门静脉血栓形成风险增加。

Liver Transpl. 2015 Aug;21(8):1016-21. doi: 10.1002/lt.24134. Epub 2015 Jul 1.

Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.美国非酒精性脂肪性肝病伴晚期肝纤维化的沉重负担：对2011 - 2014年国家健康与营养检查调查的横断面分析

Aliment Pharmacol Ther. 2017 Nov;46(10):974-980. doi: 10.1111/apt.14327. Epub 2017 Sep 15.

引用本文的文献

Inter- and intra-observer agreement in ultrasound diagnosis of steatotic liver disease: implications for screening in resource-limited settings.超声诊断脂肪性肝病的观察者间和观察者内一致性：对资源有限环境下筛查的意义。

Sci Rep. 2025 Aug 14;15(1):29819. doi: 10.1038/s41598-025-07862-1.

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis.呼吁将有风险的代谢功能障碍相关脂肪性肝炎的诊断率提高一倍。

Lancet Reg Health Eur. 2025 Jun 4;54:101320. doi: 10.1016/j.lanepe.2025.101320. eCollection 2025 Jul.

Prevalence of advanced liver fibrosis in the general population of the Paris region according to FIB-4 score and liver risk score.根据FIB-4评分和肝脏风险评分评估巴黎地区普通人群中晚期肝纤维化的患病率。

BMC Gastroenterol. 2025 Jul 1;25(1):454. doi: 10.1186/s12876-025-03992-y.

Prognostic Value of the TLM3 Biomarker Panel for Early Fibrosis Development in MASLD Within the General Population.TLM3生物标志物组合对普通人群中MAFLD早期纤维化发展的预后价值

Liver Int. 2025 Jul;45(7):e70169. doi: 10.1111/liv.70169.

Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.通过组学技术解析代谢功能障碍相关脂肪性肝病

Int J Mol Sci. 2025 Feb 13;26(4):1589. doi: 10.3390/ijms26041589.

Prevalence of advanced hepatic fibrosis and individualization of associated risk factors by Bayesian analysis in MASLD patients in French cardio-metabolic health networks.法国心血管代谢健康网络中MASLD患者晚期肝纤维化的患病率及相关危险因素的贝叶斯分析个体化

PLoS One. 2025 Jan 30;20(1):e0316158. doi: 10.1371/journal.pone.0316158. eCollection 2025.

Forns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study.Forns 指数和脂肪肝指数与血糖、糖尿病前期和 2 型糖尿病的指标相关，但 FIB-4 无关：马斯特里赫特研究分析。

BMJ Open Gastroenterol. 2024 Nov 29;11(1):e001466. doi: 10.1136/bmjgast-2024-001466.

[Not Available].[无可用内容]

Adv Lab Med. 2024 Feb 14;5(2):131-147. doi: 10.1515/almed-2023-0172. eCollection 2024 Jun.

Serum biomarkers for liver fibrosis assessment.用于肝纤维化评估的血清生物标志物。

Adv Lab Med. 2023 Nov 14;5(2):115-130. doi: 10.1515/almed-2023-0081. eCollection 2024 Jun.

Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort.与代谢功能障碍相关脂肪性肝病患者高费用相关的因素：一项使用法国CONSTANCES队列的观察性研究

Clin Diabetes Endocrinol. 2024 Apr 25;10(1):9. doi: 10.1186/s40842-023-00163-4.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献